10th Anniversary Inflammation and Immune Diseases Drug Discovery and Development Summit

Bibliography

• MESSMER D, YANG H, TELSUMA G et al.: High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. (2004) 173:307-313.
   PubMed Web of Science ®Google Scholar
• WANG H, YANG H, CZURA CJ, SAMA AE, TRACEY KJ: HMBG1 as a late mediator of lethal systemic inflammation. Am. J. Crit. Care Med. (2001) 164:1768-1773.
   Web of Science ®Google Scholar
• UENO H, MATSUDA T, HASHIMOTO S et al.: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am. J. Resp. Crit. Care Med. (2004) 170:1310-1316.
   PubMed Web of Science ®Google Scholar
• JIANG W, LI J, GALLOWITSCH-PUERTA M, TRACEY KJ, PISETSKY DS: The effects of CpG DNA on HMGB1 release by murine macrophage cell lines. J. Leukoc. Biol. (2005) 78:930-936.
   PubMed Web of Science ®Google Scholar
• EMERY P, FLEISCHMANN R, FILIPOWICZ-SOSNOWSHA A et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum. (2006) 54:1390-1400.
   PubMed Web of Science ®Google Scholar
• COHEN SB, GREENWALD M, DOUGADOS MR et al.: Efficacy and safety of rituximab in active RA patients whoexperienced an inadequate response to one or more anti-TNF therapies (REFLEX study). ACR (2005):1830 (Abstract).
   Google Scholar
• KHOBZAOUL M, GUTKE HJ, BURNET M: CC-10004. Curr. Opin. Invest. Drugs (2005) 6:518-525.
   PubMedGoogle Scholar
• GOTTLIEB AB, MALAVIYA R, ROHANE P, JONES M: Biological activity of CC-10004 in patients with severe plaque-type psoriasis. J. Am. Acad. Dermatol. (2006) 54:AB9 (Abstract p34).
   Google Scholar
• DAWSON J, MILTZ W, MIR AK, WIESSNER C: Targeting monocyte chemoattractant protein-1 signalling in disease. Expert. Opin. Ther. Targets (2003) 7:35-48.
   PubMed Web of Science ®Google Scholar
• MURRAY CM, HUTCHINSON R, BANTICK JR et al.: Monocarboxylate transporter MCT1 is a target for immunosuppression. Nat. Chem. Biol. (2005) 1:371-376.
   PubMed Web of Science ®Google Scholar
• UEHARA T, BENNETT B, SAKATA ST et al.: JNK mediates hepatic ischemia reperfusion injury. J. Hepatol. (2005) 42:850-859.
   PubMed Web of Science ®Google Scholar
• UEHARA T, XI PENG, X, BENNETT B et al.: c-Jun N-terminal kinase mediates hepatic injury after rat transplantation. Transplantation (2004) 78:324-332.
   PubMed Web of Science ®Google Scholar
• CAMPS M, RUCKLE T, JI H et al.: Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. (2005) 11:936-943.
   PubMed Web of Science ®Google Scholar
• BORHANI DW, CALDERWOOD DJ, FRIEDMAN MM et al.: A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg. Med. Chem. Lett. (2004) 14:2613-2616.
   PubMed Web of Science ®Google Scholar
• STACHLEWITZ RF, HART MA, BETTENCOURT B: A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. J. Pharmacol. Exp. Ther. (2005) 315:36-41.
   PubMed Web of Science ®Google Scholar
• BURCHAT A, BORHANI DW, CALDERWOOD et al.: Discovery of A-770041. A src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg. Med. Chem. Lett. (2006) 16:118-122.
   PubMed Web of Science ®Google Scholar
• WATTANASIN S, KALLEN J, MYERS S et al.: 1,4-diazepane-2,5-diones as novel inhibitors of LFA-1. Bioorg. Med. Chem. Lett. (2005) 15:1217-1220.
   PubMed Web of Science ®Google Scholar
• WEITZ-SCHMIDT G, WEIZENBACH K, DAWSON J, KALLEN J: Improved lymphocyte function-associated antigen (LFA-1) inhibition by statin derivatives. J. Biol. Chem. (2004) 279:46764-46771.
   PubMed Web of Science ®Google Scholar
• ULLRICH T, BAUMANN K, WELZENBACH K et al.: Statin-derived 1,3-oxazian-2-ones as submicromolar inhibitors of LFA-1–ICAM-1 interaction: stabilization of the metabolically labile vanillyl side chain. Bioorg. Med. Chem. Lett. (2004) 14:2483-2487.
   PubMed Web of Science ®Google Scholar
• WEITZ-SCHMIDT G: Statins as anti-inflammatory agents. Trends Pharmacol. Sci. (2002) 23:482-486.
   PubMed Web of Science ®Google Scholar
• WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7:687-692.
   PubMed Web of Science ®Google Scholar
• VENABLE JD, CAI H, CHAI W et al.: Preparation and biological evaluation of indole, benzimidazole and thienopyrrole piperazine carboxamides: potent histamine H4 antagonists. J. Med. Chem. (2005) 48:8289-8298.
   PubMed Web of Science ®Google Scholar
• VARGA C, HORVATH K, BERKO A et al.: Inhibitory effects of histone H4 receptor antagonists on experimental colitis in the rat. Eur. J. Pharmacol. (2005) 522:130-138.
   PubMed Web of Science ®Google Scholar
• DE LESCH IJP, THURMOND RL, JONGEJAN A, LEURS R: The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol. Sci. (2005) 26:462-469.
   PubMed Web of Science ®Google Scholar
• LIM HD, VAN RIJN RM, LING P et al.: Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J. Pharmacol Exp. Ther. (2005) 314:1310-1321.
   PubMed Web of Science ®Google Scholar
• FUNG-LEUNG W-P, THURMOND RL, LING P, KARLSSON L: Histamine H4 receptor antagonists: the new antihistamines. Curr. Opin. Investig. Drugs (2004) 5:1174-1183.
   PubMedGoogle Scholar
• THURMOND RL, DESAI PJ, DUNFORD PJ et al.: A potent and selective histamine H4 receptor antagonist with anti-iinflammatory properties. J. Pharmacol. Exp. Ther. (2004) 309:404-413.
   PubMed Web of Science ®Google Scholar
• JABLONOWSKI JA, GRICE CA, CHAI W et al.: The first potent and selective non-imidazole human histamine H4 receptor antagonists. J. Med. Chem. (2003) 46:3957-3960.
   PubMed Web of Science ®Google Scholar
• JABLONOWSKI JA, CARRUTHERS NI, THURMOND RL: The histamine H4 receptor and potential therapeutic uses for H4 ligands. Mini-rev. Med. Chem. (2004) 4:993-1000.
   PubMed Web of Science ®Google Scholar
• SAUDER DN: Imiquimod: modes of action. Br. J. Dermatol. (2003) 149(Suppl. 66):5-8.
   PubMed Web of Science ®Google Scholar
• TRAN H, CHEN K, SHUMACK S et al.: Summary of actinic keratosis studies with imiquimod 5% cream. Brit. J. Dermatol. (2003) 149(Suppl. 66):37-39.
   PubMedGoogle Scholar
• PACIOTTI GF, MYER L, WEINREICH D et al.: Colloidal gold: a novel nanoparticle vector for tumour directed drug delivery. Drug Delivery (2004) 11:169-183.
   PubMed Web of Science ®Google Scholar